Brian Stwalley

Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067

Meredith M. Regan, Charlene Mantia, Lillian Werner et al. · Journal for ImmunoTherapy of Cancer · 2021 · 36 citations · Full text

Life Sciences, Immunology, Oncology +17

Inpatient and outpatient treatment patterns of cancer-associated thrombosis in the United States

Jian Guo, Patrick Hlavacek, Tayla Poretta et al. · Journal of Thrombosis and Thrombolysis · 2020 · 23 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States

Kevin Kalinsky, Laura M. Spring, Clinton Yam et al. · Breast Cancer Research and Treatment · 2024 · 19 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival

Jeffrey S. Weber, Tayla Poretta, Brian Stwalley et al. · Cancer Immunology Immunotherapy · 2022 · 13 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

713P Treatment-free survival, with and without toxicity, after immuno-oncology vs targeted therapy for advanced renal cell carcinoma (aRCC): 42-month results of CheckMate 214

Meredith M. Regan, Opeyemi A. Jegede, Charlene Mantia et al. · Annals of Oncology · 2020 · 12 citations

Medicine, Oncology, Immunotherapy +9